Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

NCT05019742 is registered in ClinicalTrials.gov with Shanghai Pharma Biotherapeutics USA Inc. as lead sponsor.

NCT NCT05019742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05019742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
Lead sponsor
Shanghai Pharma Biotherapeutics USA Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 21, 2022
Completion date
November 1, 2022
Enrollment
3 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis